Overall, our results support an association between plasma NfL and multi-modal neuroimaging features in AD-vulnerable regions, providing insight into NfL as a potential biomarker for tracking disease progression and facilitating its proper use in AD research and therapeutic trials. This evidence concerns the gene NEFL and Alzheimer disease.